Is CYBIN INC. (HELP) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 51.5% / 30% | 2.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 51.5% / 33% | 2.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 52.2% / 33% | 2.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 51.5% / 33% | 2.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 52.2% / 33% | 2.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -55.9% | |
| Return on Assets (ROA) | -31.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$101M |
| Free Cash Flow | -$103M |
| Total Debt | $0 |
| Current Ratio | 13.8 |
| Total Assets | $259M |
Price & Trading
| Last Close | $4.65 |
| 50-Day MA | $6.33 |
| 200-Day MA | $6.78 |
| Avg Volume | 836K |
| Beta | 0.9 |
|
52-Week Range
$4.41
| |
About CYBIN INC. (HELP)
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CYBIN INC. (HELP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CYBIN INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CYBIN INC.'s debt ratio?
CYBIN INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are CYBIN INC.'s key financial metrics?
CYBIN INC. has a market capitalization of $226M. Return on equity stands at -55.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.